CEL-SCI CORP (CVM) Stock Price, Quote, News and Summary
NYSEARCA:CVM - American Stock Exchange - US1508376076 - Common Stock
CVM Quote and Key Statistics
CEL-SCI CORP
NYSEARCA:CVM (1/17/2025, 8:04:00 PM)
After market: 0.397 -0.01 (-1.39%)0.4026
+0 (+0.9%)
CVM Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -120.91% | ||
| ROE | -343.45% | ||
| Debt/Equity | 1 |
CVM Performance and Technical Analysis
CVM Ownership and Analysts
CVM Latest News and Analysis
Which stocks are moving on Monday?
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Top movers analysis in the middle of the day on 2024-12-30: top gainers and losers in today's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
What's going on in today's pre-market session
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
CEL-SCI Announces Closing of $5 Million Offering
About CVM
Company Profile
CEL-SCI Corp. is a biotechnology company, which engages in the research, development and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The firm is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.
Company Info
CEL-SCI CORP
Suite 802, 8229 Boone Blvd .
Vienna VIRGINIA 22182 US
CEO: Geert Kersten
Employees: 44
Company Website: https://cel-sci.com/
Investor Relations: https://cel-sci.com/new-investor-information/
Phone: 17035069460
CVM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.96 | 303.17B | ||
| AMGN | AMGEN INC | 14.16 | 146.27B | ||
| GILD | GILEAD SCIENCES INC | 20.73 | 114.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 827.45 | 108.68B | ||
| REGN | REGENERON PHARMACEUTICALS | 15 | 74.90B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.76B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.97B | ||
| ONC | BEIGENE LTD-ADR | N/A | 22.37B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.61 | 20.48B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.76 | 16.02B |